Biopharmaceutical company Kiadis Pharma announces that it has successfully completed treatment of the last patient on its ATIR(TM) phase I/II clinical trial. ATIR(TM), a donor lymphocyte cell based product, is under development to prevent acute Graft versus Host Disease (GvHD) and allow early immune reconstitution following a mismatched bone marrow transplantation.
[Sadece Üyeler Görebilir. Üye olmak için tiklayiniz...]
Kiadis Pharma Announces Positive Clinical Results For ATIR(TM) In Mismatched Bone Marrow Transplanta
Normal Mod
